cyrilzakka/clinical-trials huggingface dataset:
Immediate Effects of Kinesio Taping and Manual Release in Young Adults With Pes Planus

Pes planus is a postural deformity seen with decreased medial longitudinal arch (MLA) height and this causes intense stress on the plantar fascia. Pes planus may affect individuals' activities of daily living, their productivity in occupational environments, and the risk of injury and performance in sports; It has also been reported that it may cause different musculoskeletal diseases such as plantar fasciitis, medial tibial stress syndrome, patellofemoral disorders and back pain in the future. Many clinical methods are used as a treatment for pes planus and most treatments involve supporting an overstretched plantar fascia and weakened MLA. The aim of the study is to investigate the immediate effects of kinesio taping and manual release on lower extremity performance in young adults with pes planus.

This study is a randomized controlled trial, will be carried out on volunteer individuals with pes planus aged between 18-25, studying at Ankara Yıldırım Beyazıt University. Evaluation of parameters and inclusion criteria, kinesio taping and manual release applications will be made by the Physiotherapist. Individuals who meet the inclusion criteria, who volunteered to participate in the study and signed the consent sheet will be randomly divided into two groups, Group 1 \[Manual Release (MR)\] and Group 2 \[Kinesio Taping (KT)\]. A simple randomization method will be used with opaque sealed envelopes containing "1" or "2". Group allocation will be performed by an independent therapist, not involved in the study. All individuals will be evaluated with timed up-and-go test, heel rise test, 10-meter walking test, and functional reach test before and after the intervention. Manual release will be applied to group 1 after the evaluation and the evaluations will be repeated immediately the end of the application. Kinesio taping will be applied to group 2 after the evaluation and the evaluations will be repeated 45 minutes after the end of the application.

Eligibility Criteria:
Inclusion Criteria:

* Individuals who volunteer to participate in the study
* Individuals with bilateral pes planus
* Individuals who have not had any ankle injury in the last 6 months

Exclusion Criteria:

* Individuals with severe visual and hearing impairment
* Individuals with congenital shortness or deformity in their lower extremities
* Individuals who have had any lower extremity surgery
* Individuals with hallux valgus, hallux rigidus, or calcaneal epine
* Individuals with any musculoskeletal problem other than pes planus and systemic, neurological problems
* Individuals with chronic ankle instability
* Individuals who have had problems walking for the last 6 months
* Individuals who have received treatment for pes planus in the last 6 months and use insoles
Effect of Food on the Pharmacokinetics of XZP-3287 in Healthy Subjects

This study will be a randomized 3-treatment, cross-over study to evaluate the bioavailability of XZP-3287 administered after a high or low-fat meal.


Eligibility Criteria:
Inclusion Criteria:

Inclusion Criteria

1. Healthy male or female subjects aged 18 to 65 years (including 18 and 65);
2. Male body weight ≥50kg, female body weight ≥45kg, body mass index between 18 to 28 kg/m2 (inclusive).
3. No medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
4. Subjects shall ake effective contraceptive measures voluntarily within 3 months from the date of signing the informed consent form (for women, 2 weeks before trial screening) to the date of the last medication.
5. Willing and able to comply with all scheduled visits, study procedures, and provides written informed consent

Exclusion Criteria:

1. Allergic constitution and those with known allergy to XZP-3287 or similar drugs and excipients
2. Abnormal clinical tests and clinical significance judged by the investigator
3. Frequent use of sedatives, sleeping pills or other addictive drugs within 6 months before enrollment
4. History of drug use, or drug abuse screening positive
5. Those who had smoked more than 5 cigarettes per day on average in the 3 months before the screening period or habitually used nicotine-containing products and were unable to quit during the test period
6. Heavy drinking or regular drinking in the six months preceding the screening period
7. Use of any prescription drug or Chinese herbal medicine within 4 weeks prior to enrollment, or use of any over-the-counter drug, any vitamin product, health care drug within 14 days prior to enrollment;
8. Treatment with an investigational drug within 3 months
9. Participated in blood donation with blood donation volume ≥400 mL or received blood transfusion within 3 months before screening.
10. Had a severe infection, trauma or major surgery within 4 weeks of screening
11. Gastrointestinal disorders causing clinically significant symptoms such as nausea, vomiting, and diarrhea, or malabsorption syndromes
12. Pregnant or lactating women, or subjects cannot take strict contraceptive measures as required.
13. Hepatitis B surface antigen or E antigen, hepatitis C antibody, HIV antibody and syphilis antibody, any of which are positive.
14. Allergic to any food ingredients or has special requirements on diet, cannot follow the unified diet
15. habitual consumption of food or beverage containing methylxanthine, such as tea, coffee, cola, chocolate and so on during the study period
16. habitual consumption of grapefruit juice during the study period
17. have difficulty in blood collection or cannot tolerate vein puncture for blood collection
18. As determined by the investigator, the subject has other factors that are not suitable for the study -
Assessing the Effects of Mechanical Unloading on Repair Version-1

The mechanism by which heart failure initiates and progresses and the mechanisms of heart repair remain unclear.

The left ventricular assist device (LVAD) is a therapy to stabilise patients while they await their transplant. The LVAD helps pump blood around the body, giving the heart an opportunity to recover. During surgery, the apical core tissue is routinely removed to allow the implantation of the device (this tissue is normally discarded). Some patients demonstrate cardiac recovery, allowing the device to be removed without later needing a transplant. As part of the LVAD removal procedure, the section around the device might need to be removed (this tissue is normally discarded). To further understand the cellular and molecular mechanisms by which the heart is repaired, the investigators wish to utilise this surplus tissue for research purposes. The collection of this tissue is part of routine treatment and does not represent additional risk for the patient for research purposes. Some patients might still require a transplant following VAD treatment. The native heart is removed from these patients (routinely discarded) and replaced by a donor heart. The investigators wish to utilise this discarded tissue for research purposes, so that the investigators can identify the cellular and molecular factors involved in cardiac repair and which distinguish responsive and non-responsive patients. Heart transplant recipients who require extracorporeal membrane oxygenation will have an additional heart biopsy sample taken for research purposes when performed as part of routine clinical practice. There is no additional risk to the patient for research purposes. Heart failure patients scheduled for transplantation (who have not received a VAD) will be recruited prior to transplantation and their native heart retained for research purposes. An additional peripheral blood sample will be collected from all patients for research purposes when performed for routine clinical practice.


Eligibility Criteria:
Inclusion Criteria:

* Patients must be able to provide informed consent; informed consent may be provided retrospectively if this cannot be provided pre-surgery.
* Patients must be aged between 18--70 years of age.
* Patients who have been clinically diagnosed with chronic heart failure and require mechanical unloading using a left ventricular assist device.
* Patients who have received a heart transplant but require extracorporeal membrane oxygenation.

Exclusion Criteria:

* Patients under 18 or over 70 years of age.
* Patients unable to provide informed consent.
* Patients who are prisoners.
Comparison of Liagure Safety in Thyroidectomy With Conventional Thyroidectomy

To compare intraoperative and postoperative complication rates in thyroidectomy between ligasure and traditional vascular ligation and clipping .

Due to the high vascularity of the thyroid gland and the relatively tiny operative field, rigorous hemostasis is an essential requirement for successful thyroid surgery. Blood vessel ligation and/or ligation are the primary means of attaining hemostasis in thyroidectomy. New technologies have been developed, including a vessel sealing device (ligasure) that seals vessels by fusing the inner layers of the vessel wall with minimal amounts of thermal dispersion burning and tissue friction, thereby minimizing the occurrence of unintentional burns.

yet. It is unclear whether the heat conveyed by a ligature can harm the recurrent laryngeal nerve due to its proximity to the berry ligament.

thromosis of the inferior parathyroidal gland's supplying artery during dissection may result from alternative prospective delineation of the inferior thyroidal artery using ligasure for dissection.

The purpose of this study is to assess the safety and efficacy of ligasure with standard vascular ligation in open thyroid surgery.

Eligibility Criteria:
Inclusion Criteria:

Patient who will undergo lobectomy , subtotal thyroidectomy , total thyroidectomy at time of study

Any age

-

Exclusion Criteria:

* patient undergoing re-do surgery " completion thyroidectomy "

patient undergoing concomitant procedures as cervical lymphadenectomy or parathyroidectomy
Study of the Facial Nerve in MRI 3T in the Preoperative Assessment of Parotid Tumors

Preoperative evaluation of the precise localization of the intrapartotic facial nerve is essential for the ENT surgeon to assess the risk of nerve damage during parotid tumor excision, and inform the patient of the risk of post-paralyzed facial nerve palsy. procedure

1. st visit: Inclusion, parotid MRI 3Tesla high resolution with specific sequences and gadolinium injection performed at the A. de Rothschild Foundation. Evaluation by two radiologists of the exact position of the parotid tumor with respect to the trunk of the facial nerve and its first branches, classified into two categories: contact (≤ 5 mm) or distance (\> 5 mm).
2. nd visit: Surgical intervention of the parotid tumor. The surgeon will specify the same data as those collected by the radiologists after the MRI. The surgeon will not be aware of the data concerning the ratios of parotid tumor to facial nerve collected on MRI sequences for research purposes.

Eligibility Criteria:
Inclusion Criteria:

* Patient over 18 years old
* Patient seeking first-line surgery for a parotid tumor (single or multiple, benign or malignant)
* Parotidian tumor located near the trunk of the facial nerve and / or its first division branches (temporofacial and cervicofacial), during a clinical evaluation performed by the surgeon in preoperative consultation
* Patient affiliated or beneficiary of a social security scheme
* Written consent to participate in the study

Exclusion Criteria:

* Personal history of ipsilateral parotid surgery
* Contraindication to MRI (electronic device, metallic foreign body, claustrophobia)
* Known hypersensitivity to gadolinium contrast agents
* Renal impairment known: glomerular filtration rate \<30 mL / min
* Pre or post-operative period of liver transplantation
* Patient benefiting from a legal protection measure
* Pregnant or lactating woman
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.


Eligibility Criteria:
Key Inclusion Criteria:

* Forced expiratory volume in 1 second (FEV1) value ≥30% and ≤90% predicted
* Heterozygous for CF transmembrane conductance regulator gene (CFTR) F508del mutation and a minimal function mutation (F/MF genotypes)

Key Exclusion Criteria:

* Clinically significant liver cirrhosis
* Solid organ or hematological transplantation
* Non-ambulatory status
* Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply.
Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.

This study is a randomized, open-label, 2-way, 2-period, single-dose crossover clinical study to compare the pharmacokinetic characteristics and the safety between zeropix tablet 1 mg and champix® tablet 1 mg in healthy adult male subjects


Eligibility Criteria:
Inclusion Criteria:

1. Healthy male older than 19 to 45 years at the time of screening
2. Body weight more than 50kg and Body Mass Index(BMI) 18\~29 kg/m2 ☞ BMI = (weight \[kg\])/(height \[m\])2 3. Subject judged to be eligible by physical examination and interview conducted according to the study protocol. Thus, Subject should not have congenital/chronic disease or pathological symptoms/findings

Exclusion Criteria:

1. Subject currently with or has a history of cardiovascular , respiratory, hepatic, renal, neurological, endocrine, hemato-oncology, psychiatric, urinary diseases that is clinically significant
2. Subject with a history of significant hypersensitivity or clinically significant hypersensitivity reaction to varenicline and other drugs (aspirin, antibiotic...etc.)
3. Systolic blood pressure ⩽100mmHg or ⩾ 150mmHg, diastolic blood pressure⩽55mmHg or ⩾ 95mmHg
4. Subject with a history of gastrointestinal disease (i.e. Crohn's disease, ulcer...etc.) or gastrointestinal surgery (not including, simple appendectomy or hernia surgery) that can affect drug absorption
5. Subject with the following results in the clinical laboratory tests

   * Aspartate Transaminase(AST) or Alanine Transaminase(ALT) \> 2 x upper limit of normal range
   * Total Bilirubin \> 2.0 mg/dl
   * CK \> 2 x upper limit of normal range
   * eGFR \< 60 mL/min/1.73m2
6. Subject who takes alcohol \> 21 units/week, 1unit=10g=12.5ml of pure alcohol) or can't stop drinking during the clinical trials
7. Subject who smokes\> 10 cigarettes/day or can't stop smoking during the clinical trials
Impact of Intrathecal Morphine on Sleep Apnea Syndrome

Intrathecal morphine is commonly used as an analgesic adjunct for hip arthroplasty performed under spinal anaesthesia. Sleep apnea syndrome is a condition that affects up to 10% of the patients. Effect of intrathecal hydrophilic opioids on the frequency and duration of apneic episodes is unknown. The objective of this randomised controlled trial is to investigate the effect of intrathecal morphine and surgery on apneic episodes.


Eligibility Criteria:
Inclusion Criteria:

* physical status I - III
* patients scheduled to undergo hip arthroplasty

Exclusion Criteria:

* planned surgical duration more than 3 hours
* contraindication to spinal anaesthesia
* severe respiratory disease
* patient known and treated for sleep apnea syndrome
Metabolic Syndrome and Female Breast Cancer

The role among metabolic syndrome and breast cancer risk is not well understood and must be further explored. The objective of this study is to evaluate the association between metabolic syndrome and breast cancer in Southern Brazil. In this case-control study, breast cancer patients and controls without malignant disease, matched for age (±5 years) and menopausal status, were interviewed and asked to make a glucose, HDL-cholesterol and triglycerides test. Waist circumference and blood pressure were measured using standardized procedures. Metabolic Syndrome was considered by NCEP ATP III (2001) and IDF (2006) definitions. Cases and controls were compared in relation to the presence of diagnosed MetS (yes/no), number of metabolic abnormalities identified (1 to 5) for each definition, and according to each metabolic abnormality cutoff point.


Eligibility Criteria:
Inclusion Criteria:

* For cases: having newly diagnosed breast cancer without adjuvant or neoadjuvant treatment;
* For controls: having no evidence of cancer; be matched for age and menopausal status with controls

Exclusion Criteria:

* Women with a recidivated tumor, HIV infection, renal, heart or liver disease, hypothyroidism or hyperthyroidism, mobility or neurological limitations, chronicle use of corticosteroids, pacemakers or identified with severe edema were excluded.
Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis

In this phase II clinical trial, the pharmacokinetics, safety and (short-term) efficacy of higher than standard doses rifampicin will be studied during the intensive phase of tuberculosis (TB) treatment. Patients enrolled in this study will either get the standard TB regimen (including 600 mg rifampicin; first study arm), or 900 mg rifampicin plus isoniazid, ethambutol and pyrazinamide in standard dosages (second study arm), or 1200 mg rifampicin plus the other drugs in standard dosages (third study arm). All patients will get the standard TB regimen during the continuation phase of treatment.


Eligibility Criteria:
Inclusion Criteria:

* Participant has a newly diagnosed pulmonary tuberculosis, confirmed by a positive smear of at least two sputum specimens with ZN staining.
* Participant is willing to be tested for HIV.
* Participant is at least 18, but not more than 65 years of age at the day of the first dosing of study medication.
* Participant is admitted to KNTH or KCMC during the intensive phase of TB treatment.
* Participant is able and willing to attend to KNTH or KCMC regularly during the continuation phase of TB treatment.
* Participant is able to understand and willing to sign the Informed Consent Form prior to screening evaluations.
* Female participants should understand that it is important not to get pregnant during the study. They should agree on taking measures to prevent them from getting pregnant during the study. They should agree on taking measures to prevent them from getting pregnant, such as using a contraceptive device or barrier method.

Exclusion Criteria:

* Participant has been treated with anti-tuberculosis drugs during the past three years.
* Participant's body weight is less than 50 kg.
* Participant has abnormal liver function test or serum creatinine (defined as levels higher than the upper limit of normal).
* Participant has a relevant medical history or current condition that might interfere with drug absorption, distribution, metabolism or excretion (i.e. chronic gastro-intestinal disease, Diabetes Mellitus, renal or hepatic disease, use of concomitant drugs that interfere with the pharmacokinetics of anti-TB drugs).
* Participant is on anti-retroviral treatment at inclusion.
* Participant has a CD4 count less than 350 cells/mm3.
* Participant has a Karnofsky score of less than 40.
* Participant is pregnant or breastfeeding.
* Participant has a Multi Drug Resistant (MDR)-TB for which another than the standard treatment regimen is needed.
Dynamic Scaffold Versus Lichtenstein Open Hernioplasty.

Evaluating the outcomes of patients undergoing open anterior inguinal hernioplasty comparing two different techniques: Lichtenstein/plug and mesh and ProFlor. The outcomes of these two groups of patients, respectively the Lichtenstein inguinal hernia repair with static flat mesh and the defect obliteration with 3D dynamic scaffold Proflor, are compared in respect to defined variables along stages: intraoperative, early and long term postoperative.


Eligibility Criteria:
Inclusion Criteria:

Eligible patients were individuals aged between 18 and 85 years old, competent to give consent, affected by clinically relevant primary inguinal hernia scheduled to undergo elective inguinal hernia repair and eligible for outpatient surgical procedure with local anesthesia.

Exclusion Criteria:

* Recurrent inguinal hernia
* Incarcerated inguinal hernia
* Hernia not in the inguinal area
* Signs of obvious local or systemic infection
* ASA score \> 4
* Presenting with unstable angina or NYHA class of IV
* Pregnant
* Active drug user
* Immunosuppression, chemotherapy
* Chronic renal insufficiency
* Abdominal ascites
* Infection in area of the surgical field
* BMI \>35
Prevalence of Nerd Neck Between Different Students at Taibah University, Saudi Arabia

A convenient sample of 82 female students aged 18-24 years participated in analytic observational experiment cross section design. Students were recruited into two groups, practical and non-practical. to answer the following

1. Is there a difference in the prevalence of nerd neck between students of practical and non-practical studying groups at Taibah University from the sitting position?
2. Is there a difference in the prevalence of nerd neck between students of practical and non-practical studying groups at Taibah University from the standing position?


Eligibility Criteria:
Inclusion Criteria:

* A convenient sample of 82 female students
* the age was between 18-24 years
* Students were recruited from practical and non-practical faculties at taibah university.

Exclusion Criteria:

* we excluded Any student with previous neck or back surgery or history of previous accident
* Also, any student with history of cervical column fracture injury, scoliosis, severe thoracic kyphosis, torticollis, persistent respiratory problems, rheumatic disease.
* also we excluded any student with loss of standing balance and user of hearing aid
Determination of Glycemic Index (GI) of Ten Food Products

This study is initiated to investigate the glycemic index value of ten food products.


Eligibility Criteria:
Inclusion Criteria:

* Healthy non-pregnant females (at least 6 weeks postpartum, non-lactating)
* Age between 21 to 60 years

Exclusion Criteria:

* Suffering from any chronic diseases.
* Suffering from gastrointestinal diseases that may interfere with nutrient absorption, distribution, metabolism and excretion.
* History of diabtes mellitus or use of antihyperglycemic drugs or insulin to treat diabetes and related conditions.
* History of AIDS, hepatitis, renal or heart disease or any other serious complications that may interfere with glucose metabolism.
* Current use of medication that may interfere with the digestion and nutrient absorption (for examples steriods, protease inhibitors or antipsychotics medications).
* Current use of medication known to affect glucose tolerance (excluding oral contraceptives).
* Known food allergy or intolerance.